United States · Investor

GlaxoSmithKline

Last cheque observed Apr 2019. Silence since then is not evidence of inactivity: our sources miss unannounced rounds.

QuietVC firm

Series AVentureSeries BAnalyticsAppsCloud Data Services

Cheques on record
0%of best year0cheques in 12 months, 21 on record
Since the last cheque2765days00hrs00min00sec
Median round$125MRounds led0 of 21Sole investor6 roundsExits2 from the portfolioMostly inUnited States, 75%
Pitch GlaxoSmithKline

GlaxoSmithKline highlights

  1. 01

    21 rounds on record

  2. 02

    Mostly Series A and Venture: 74% of its rounds

  3. 03

    Sole investor in 6 rounds, median $17M

  4. 04

    2 exits from the portfolio

What they do

Type
VC firm (from a list, unverified)
Cheque size
Not stated
Sectors
AnalyticsAppsCloud Data Services
Based in
London, United States
Cold pitches
Not stated

The record

Every round we can evidence, newest first21 appearances

  1. 2019

    1 round

  2. Apr
    SpringWorks TherapeuticsSeries B · US · FinSMEs$125MWith 12 others
  3. 2018

    2 rounds

  4. Oct
    SitryxGB · Pharmatimes$30MWith 2 others
  5. Jul
    23andMeUS · Forbes$300MSole investor
  6. 2015

    6 rounds

  7. Nov
    AtrecaSeries A · US$56MWith 2 others
  8. Oct
    Decibel TherapeuticsSeries A$52MWith 2 others
  9. Jun
    Gladius PharmaceuticalsSeries A · CA$3.3MWith 3 others
  10. Jun
    Spero TherapeuticsSeries A · US$30MWith 7 others
  11. Apr
    CRISPR THERAPEUTICSSeries B · GB$64MWith 5 others
  12. Apr
    ZappRxSeries A · US$5.6MWith 2 others
  13. 2014

    3 rounds

  14. Sept
    Silarus TherapeuticsSeries A · US$10MWith 1 other
  15. Sept
    Thyritope BiosciencesSeries A · US$10MWith 1 other
  16. Jul
    Isis PharmaceuticalsVenture · US$11MSole investor
  17. 2013

    2 rounds

  18. Nov
    Sitari PharmaceuticalsSeries A · US · finsmes.com$10MWith 1 other
  19. Aug
    SetPoint MedicalSeries A · US · sec.gov$31MWith 6 others
  20. 2011

    2 rounds

  21. Oct
    EpizymeVenture · US · epizyme.com$4.0MSole investor
  22. Jun
    Concert PharmaceuticalsVenture · US · masshightech.com$4.0MSole investor
  23. 2010

    3 rounds

  24. Dec
    Semprus BioSciencesSeries B · US · semprusbio.com$18MWith 4 others
  25. Nov
    TheravanceGrowth · US · files.shareholder.com$129MSole investor
  26. May
    NeuroTherapeutics PharmaSeries B · US · fiercebiotech.com$43MWith 4 others
  27. 2009

    2 rounds

  28. Oct
    GenmabVenture · DK · fiercebiotech.com$23MSole investor
  29. Jun
    Chroma TherapeuticsVenture · GB$25MWith 5 others

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

The team

We hold 22 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.

What they claim to have backed

From their own portfolio page (on their website)

0 of 3 we have independently watched raise

GskproSupplierViiV Healthcare

Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.

Exits from the portfolio

Companies it backed that were later bought or listed2 in all

EpizymeListed$60MMay 2013
Semprus BioSciencesBought by Teleflex$30MJun 2012

An exit counts when it came after the firm's first round in the company. From historical deal records.

Companies it bought

Acquisitions by the firm itself

Okairos$325MMay 2013
Human Genome Sciences$3.0BAug 2012
NovaMin TechnologyUndisclosedMay 2010
Stiefel$3.6BApr 2009
Genelabs Technologies$57MNov 2008
Sirtris Pharmaceuticals$720MApr 2008
Reliant Pharmaceuticals$1.6BNov 2007
CNSUndisclosedDec 2006

Who they invest alongside

The investors most often in the same rounds as GlaxoSmithKline. A count of rooms they were both in, not a relationship either has claimed.

SR OneCorporate VC7rounds togetherAvalon VenturesVC firm3rounds togetherAbingworthVC firm2rounds togetherAtlas VentureVC firm2rounds togetherFoundation Medical PartnersPrivate equity2rounds together

Recently backed

The latest companies GlaxoSmithKline put money into.

SpringWorks Therapeutics$125M · Apr 2019Sitryx$30M · Oct 201823andMe$300M · Jul 2018

Quick answers about GlaxoSmithKline

What does GlaxoSmithKline invest in?

GlaxoSmithKline invests most often at Series A and Venture (74% of the rounds on record), in sectors such as Analytics, Apps and Cloud Data Services.

How active is GlaxoSmithKline?

21 investments on record, 0 of them in the last 12 months. The most recent was in Apr 2019.

What has GlaxoSmithKline invested in recently?

Its most recent investments on record: SpringWorks Therapeutics (Series B, Apr 2019), Sitryx (Undisclosed round, Oct 2018) and 23andMe (Undisclosed round, Jul 2018).

How big are GlaxoSmithKline's cheques?

The median round it joins is $125M.

Does GlaxoSmithKline lead rounds?

Rarely, if at all: none of its 21 investments on record names it as the lead.

Where does GlaxoSmithKline invest?

Most of the companies it backs are in the United States (75%), the United Kingdom (15%) and Canada (5%).

Is GlaxoSmithKline investing now?

No investments in the last 12 months; the latest was in Apr 2019.

Who does GlaxoSmithKline invest alongside?

Most often SR One (7 rounds together), Avalon Ventures (3 rounds together) and Abingworth (2 rounds together).

Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Find similar investorsOpen your CRM

Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it